Table 5.
Postmortem studies of endocannabinoid metabolism in psychotic disorders.
|
1Metabolic enzymes |
||||||
|---|---|---|---|---|---|---|
| Condition & brain region | n (cases/controls) | AEA/PEA/OEA | 2-AG | AEA | 2-AG | Reference |
| Dorsolateral prefrontal cortex | ||||||
| Schizophrenia | 42/42 | - | - | - | n.s. DAGL | Volk et al., 2010 |
| n.s. MAGL | ||||||
| Schizophrenia | 42/42 | - | - | - | n.s. ABHD6 | Volk et al., 2013 |
| >15 years duration2 | 30/42 | n.s.ABHD6 | ||||
| <15 years duration2 | 12/42 | ↑ABHD6 | ||||
| Schizophrenia | 19/19 | n.s.AEA | ↑ | n.s. FAAH, ↑FAAH activity |
n.s. MAGL |
Muguruza et al., 2013; Muguruza et al., 2019 |
| n.s.PEA | ||||||
| n.s.OEA | ||||||
| Superior frontal gyrus (anterior) | ||||||
| Schizophrenia | 27/396 | n.s.AEA | ↑ | - | - | (Yu et al., 2018) |
| Hippocampus | ||||||
| Schizophrenia | 19/19 | ↓AEA | ↑ | - | - | (Muguruza et al., 2013) |
| n.s.PEA | ||||||
| n.s.OEA | ||||||
| Cerebellum | ||||||
| Schizophrenia | 19/19 | ↓AEA | n.s. | - | - | (Muguruza et al., 2013) |
| ↓PEA | ||||||
| n.s.OEA | ||||||
↑: higher; ↓: lower; n.s: no significant difference from controls; -: no available data;
AEA: anandamide; PEA: N-palmitoylethanolamide; OEA: N-oleoylethanolamide; 2-AG: 2-arachidonoyglycerol; NAPE-PLD: N-acyl phosphatidylethanolamine phospholipase D; FAAH: fatty acid amide hydrolase; DAGL: diacylglycerol lipase; MAGL: monoacylglycerol lipase; ABHD6: α/β-hydrolase domain-containing 6;
1
Results reflect mRNA levels unless noted as enzyme activity.
2
This is a subgroup within Volk et al., 2013 study.